Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 640 results for "clopidogrel"

1 images for "clopidogrel"

MDLinx, 3 weeks ago

Human medicines European public assessment report (EPAR): Iscover, clopidogrel, Revision: 31, Authorised

This is a summary of the European public assessment report (EPAR) for Iscover. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency1 month ago

Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents

The authors reply: We appreciate the interest in our study. In reply to Sipahi: in the clopidogrel-treated subgroup (6500 patients), the number of new cancers reported was 73 in the group that continued to receive thienopyridine and 55 in the ...
 New England Journal of Medicine1 month ago Optimal duration of dual antiplatelet therapy after drug eluting stent remains unclear  British Medical Journal1 day ago Dual Perspectives on DAPT  Orthopedics Today1 week ago Dual Antiplatelet Therapy After PCI With Drug Eluting Stents  General Medicine eJournal2 weeks ago
[x]  

Clopidogrel Interruption Does Not Increase Risk of Post-Polypectomy Bleeding: Presented at DDW

You currently are not registered for any FirstWord Pharma services. Register to FirstWord Pharma for free access to 10 articles every 30 days: You can also: Wait 26 days for your content allowance to be renewed. Sign up for a free trial to ...
 FirstWord Pharma6 days ago Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel for Ad Hoc PCI Patients  Diagnostic & Invasive Cardiology1 week ago Ticagrelor More Effective Than Clopidogrel in Low-Risk Patients Undergoing PCI: Presented at SCAI  FirstWord Pharma2 weeks ago SCAI Release: Antiplatelet Drug Ticagrelor More Effective Than Clopidogrel For Ad Hoc PCI Patients 5/7/2015  ClinicSpace2 weeks ago
[x]  

Real-World Data Show Prasugrel Is More Likely to Be Used in Low-Risk Patients

Compared to Clopidogrel, Prasugrel Did Not Have a Higher Risk of Bleeding at 90 Days 12:05 ET from SCAI SAN DIEGO, May 8, 2015 /PRNewswire/ -- Prasugrel (Effient®) is more likely to be given to lower-­risk heart disease patients undergoing ...
 PR Newswire2 weeks ago Prasugrel More Likely Candidate for Low-Risk Heart Disease Patients  Diagnostic & Invasive Cardiology1 week ago
[x]  
BioSpace

McCormack Pharma's Discovery Could Mean New Guidelines For Anti-Platelet Drug Use

Clopidogrel (Plavix) is an anti-platelet drug that is used to prevent the formation of a thrombus (clot) in vulnerable patients. However, a significant proportion of patients who receive clopidogrel remain at risk for subsequent death, myocardial ...
 PharmaceuticalProcessing1 month ago McCormack Pharma's Landmark Discovery could mean New Guidelines for use of Anti-Platelet Drug  TickerTech.com1 month ago McCormack Pharma 's Landmark Discovery Could Mean New Guidelines For Use Of Anti-Platelet Drug  BioSpace1 month ago
[x]  

Clopidogrel Bisulfate Market 2015-2020 Research Reviews

 Securities Technology Monitor1 month ago
[x]  

ISAR-TRIPLE: Net clinical outcomes similar for 6-week vs. 6-month triple therapy

Six weeks of triple therapy with oral anticoagulation, aspirin and clopidogrel was not superior to a 6-month regimen for the primary outcome of death, MI, definite stent thrombosis, stroke or TIMI major bleeding at 9 months, according to data from ...
 Orthopedics Today3 weeks ago Duration of Triple Therapy After DES in Patients with Atrial Fibrillation  New England Journal of Medicine2 hours ago Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial  European Heart Journal6 days ago Trade-Off for Six Weeks Versus Six Months of Triple Tx Post Stent  Physician's Briefing3 weeks ago

Clopidogrel/Aspirin Combo Helps After Stroke, TIA

NEW YORK (Reuters Health) -- Three months of dual treatment with clopidogrel and aspirin after acute minor stroke or high-risk transient ischemic attack (TIA) had lasting benefit over 1 year in the CHANCE trial. The results of 1-year follow-up ...
 MedPage Today11 hours ago Dual antiplatelet therapy with clopidogrel and aspirin reduces stroke risk  Cardiovascular Business2 weeks ago Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE): 1-Year Outcomes [Original Articles]  Circulation: Cardiovascular Interventions2 weeks ago DAPT may reduce MACE, mortality in patients with symptomatic PAD  Orthopedics Today4 weeks ago

DIFFERENTIAL IMPACT OF HIGH PLATELET REACTIVITY ON CLOPIDOGREL IN WOMEN AND MEN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH DES

Note: Since your browser does not support Javascript, you must press the Continue button once
 Journal of the American College of Cardiology2 months ago Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials  Plosone.org1 day ago Stroke following percutaneous coronary intervention: type-specific incidence, outcomes and determinants seen by the British Cardiovascular Intervention Society 2007-12  European Heart Journal1 month ago HIGH PLATELET REACTIVITY IS ASSOCIATED WITH VASCULAR FUNCTION IN PATIENTS AFTER PERCUTANEOUS CORONARY INTERVENTION RECEIVING CLOPIDOGREL  Journal of the American College of Cardiology2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - clopidogrel
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less